Gene therapy for Mucopolysaccharidoses.

about

Targeting Heparan Sulfate Proteoglycans as a Novel Therapeutic Strategy for Mucopolysaccharidoses.In Vivo Genome Editing as a Therapeutic Approach

P2860

Q55331907-8CB0B45B-270A-4E8E-9770-7B6CC8CE5703 Q58745391-FE0B26E6-49BE-4AA8-989F-119657987750

P2860

Gene therapy for Mucopolysaccharidoses.

Item

http://www.wikidata.org/entity/Q47558790

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Gene therapy for Mucopolysaccharidoses.

@en

Gene therapy for Mucopolysaccharidoses.

@nl

type

Item

label

Gene therapy for Mucopolysaccharidoses.

@en

Gene therapy for Mucopolysaccharidoses.

@nl

prefLabel

Gene therapy for Mucopolysaccharidoses.

@en

Gene therapy for Mucopolysaccharidoses.

@nl

P1476

Gene therapy for Mucopolysaccharidoses

@en

P2093

Hui-Hsuan Chen

http://www.w3.org/2001/XMLSchema#string

Kazuki Sawamoto

http://www.w3.org/2001/XMLSchema#string

Robert W Mason

http://www.w3.org/2001/XMLSchema#string

Shunji Tomatsu

http://www.w3.org/2001/XMLSchema#string

P2860

Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors

Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer

Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease

Hematopoietic stem cell transplantation for Morquio A syndrome.

P304

59-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMGME.2017.12.434

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Carlos J Alméciga-Díaz

P577

2017-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29295764

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

P932

5986190

http://www.w3.org/2001/XMLSchema#string

Gene therapy for Mucopolysaccharidoses.

about

P2860

P2860

Gene therapy for Mucopolysaccharidoses.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932